{"id":7193,"date":"2020-01-09T17:54:06","date_gmt":"2020-01-09T12:24:06","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=7193"},"modified":"2021-07-24T12:57:43","modified_gmt":"2021-07-24T07:27:43","slug":"recent-pharma-happenings-for-novome-almirall-bioniz-adagene","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene","title":{"rendered":"Novome raises USD 33M, Buyout of Bioniz, Adagene raises USD 69M"},"content":{"rendered":"\n<h3 class=\"wp-block-heading\"><strong>A biotech company Novome Biotechnologies is developing novel live medicines for chronic diseases, has raised USD 33 Million in Series A financing. <\/strong><\/h3>\n\n\n\n<p>The financing was led by DCVC Bio with participation from seed investor 5AM Ventures, Alta Partners, Alexandria Venture Investments and Mayo Clinic. The company plans to use the funds to advance the Company\u2019s lead <a href=\"https:\/\/www.delveinsight.com\/report-store\/primary-hyperoxaluria-market\">hyperoxaluria <\/a>program and to expand its Genetically Engineered Microbial Medicines (GEMMs) platform.&nbsp;<\/p>\n\n\n\n<p>The company is developing a robust pipeline to treat chronic diseases that invades the human gut. The pivotal program of the company is focusing on advancing the treatment approach for hyperoxaluria.&nbsp;<\/p>\n\n\n\n<p><a href=\"https:\/\/www.delveinsight.com\/report-store\/hyperoxaluria-pipeline-insight\">Hyperoxaluria <\/a>is excessive urinary excretion of oxalate, which often results in calcium oxalate stones in the kidney. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Almirall, a Spanish biopharma company has decided to strike a deal to purchase Bioniz Therapeutics to expands its CTCL pipeline. <\/strong><\/h3>\n\n\n\n<p>Barcelona-based Almirall \u2013 which specialises in dermatology \u2013 says that the deal would expand its R&amp;D pipeline with an additional three candidates on top of lead drug BNZ-1.<\/p>\n\n\n\n<p>BNZ-1 is a selective cytokine inhibitor of IL-2, IL-9 and IL-15 and is in the early-stage trial for <a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-t-cell-lymphoma-ctcl-market\">Cutaneous T-cell lymphoma<\/a> treatment. The drug poses a potential treatment approach for alopecia areata, a form of hair loss with no FDA-approved therapies.<\/p>\n\n\n\n<p>Under the terms of agreements, the company will receive an upfront initial payment of USD 15Million in exchange for the Almirall option to acquire all Bioniz outstanding shares.&nbsp; If Almirall exercises its option, Bioniz will receive an option exercise fee of USD 47M, plus additional milestone payments and royalties.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><strong>Adagene has raised around USD69 million in a Series D financing round to advance its treatment portfolio of cancer.&nbsp;<\/strong><\/h3>\n\n\n\n<p>The company has decided to use the funds to support and advance the development of its lead clinical candidates for the treatment of cancer.<\/p>\n\n\n\n<p>ADG106 is the most advanced clinical drug of the company and is a first-in-class anti-CD137 monoclonal IgG4 antibody. The drug is at present in Phase I clinical trials for advanced or metastatic solid and liquid tumors. <br><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A biotech company Novome Biotechnologies is developing novel live medicines for chronic diseases, has raised USD 33 Million in Series A financing. The financing was led by DCVC Bio with participation from seed investor 5AM Ventures, Alta Partners, Alexandria Venture Investments and Mayo Clinic. The company plans to use the funds to advance the Company\u2019s [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7194,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[17948,17546,17946,17947,349,17945,639,5789],"industry":[17225],"therapeutic_areas":[17230,17228],"class_list":["post-7193","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-adagene","tag-almirall","tag-bioniz-therapeutics","tag-cutaneous-t-cell-lymphoma-treatment","tag-latest-pharma-news","tag-novome-biotechnologies","tag-pharma-news","tag-recent-pharma-news","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novome secured $33M; Adagene raises $69M; Almirall to acquire Bioniz<\/title>\n<meta name=\"description\" content=\"Novome plans to use the funds to advance the Company\u2019s lead hyperoxaluria program and to expand its Genetically Engineered Microbial Medicines platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novome secured $33M; Adagene raises $69M; Almirall to acquire Bioniz\" \/>\n<meta property=\"og:description\" content=\"Novome plans to use the funds to advance the Company\u2019s lead hyperoxaluria program and to expand its Genetically Engineered Microbial Medicines platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-01-09T12:24:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/09175251\/pharma_news_09.01.2020.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novome secured $33M; Adagene raises $69M; Almirall to acquire Bioniz","description":"Novome plans to use the funds to advance the Company\u2019s lead hyperoxaluria program and to expand its Genetically Engineered Microbial Medicines platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene","og_locale":"en_US","og_type":"article","og_title":"Novome secured $33M; Adagene raises $69M; Almirall to acquire Bioniz","og_description":"Novome plans to use the funds to advance the Company\u2019s lead hyperoxaluria program and to expand its Genetically Engineered Microbial Medicines platform.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-01-09T12:24:06+00:00","article_modified_time":"2021-07-24T07:27:43+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/09175251\/pharma_news_09.01.2020.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene","name":"Novome secured $33M; Adagene raises $69M; Almirall to acquire Bioniz","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/09175251\/pharma_news_09.01.2020.png","datePublished":"2020-01-09T12:24:06+00:00","dateModified":"2021-07-24T07:27:43+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Novome plans to use the funds to advance the Company\u2019s lead hyperoxaluria program and to expand its Genetically Engineered Microbial Medicines platform.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-novome-almirall-bioniz-adagene#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/09175251\/pharma_news_09.01.2020.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/09175251\/pharma_news_09.01.2020.png","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/01\/09175251\/pharma_news_09.01.2020-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Adagene<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Almirall<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bioniz Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cutaneous T Cell Lymphoma Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novome Biotechnologies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Adagene<\/span>","<span class=\"advgb-post-tax-term\">Almirall<\/span>","<span class=\"advgb-post-tax-term\">Bioniz Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">Cutaneous T Cell Lymphoma Treatment<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Novome Biotechnologies<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 9, 2020","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 9, 2020 5:54 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7193","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=7193"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/7193\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/7194"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=7193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=7193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=7193"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=7193"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=7193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}